Sunscreen Efficacy Against the Reccurence of Lesions Post-sun Exposure in Acneic Subjects
7 décembre 2021 mis à jour par: Pierre Fabre Dermo Cosmetique
Evaluation of the Cutaneous and Ocular Tolerance of RV4857A Sunscreen Product and Its Efficacy Against the Recurrence of Lesions Post Sun Exposure in Subjects With Facial Acne
The aim of this study is firstly to assess the tolerance of the sunscreen RV4857A-CD2110 after 28 days and 57 days of at least a twice daily on the study areas, secondly to assess anti-imperfection efficacy after 28 days and 57 days of use and its efficacy against recurrence of acne lesions post-sun exposure.
Aperçu de l'étude
Description détaillée
This is a monocentric study on adults and adolescents with acne prone skin on the face. This open-labelled study aim first to assess the dermatological and ophthalmological tolerance of the investigational sunscreen product RV4857A formula CD2110 after 28 days and, dermatological tolerance after 57 days of at least a twice daily on the study areas, under normal conditions of use, on 40 subjects intending to have a minimum of 10 days per month of sun exposure duration ≥ 1h, in the time slot 11am-4pm and intending to have a minimum of 4 swimming sessions (sea or swimming pool) during at least the first month of the study.
Secondary objectives :
- To assess the anti-imperfection efficacy of the product during the summer
- To assess the "non" rebound effect (non recurrence of acne) one month after stopping the application of the sunscreen and without any sun exposure at D85 (difference between D85 and D0)
- To evaluate the impact on Quality of Life of subjects through CADI and DLQI questionnaires (or CDLQI questionnaire for adolescent from 12 to 16 years-old) completed at baseline, D29 and D57
The study includes 4 visits :
- Visit 1: Inclusion visit (D1)
- Visit 2: Intermediate visit (D29)
- Visit 3: Intermediate visit "end of summer" (D57), a Stop the application of the sunscreen product (and stop sun exposure) between Visit 3 and the end of the study Visit 4: End of study visit in autumn (D85)
The theoretical study duration for each subject will be 85 days with at least 57 days of product use. The study interest areas are Face and Neck.
Type d'étude
Observationnel
Inscription (Réel)
45
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Lieux d'étude
-
-
-
Lisboa, Le Portugal, 1750-182
- PhD Trials®
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
12 ans à 40 ans (Enfant, Adulte)
Accepte les volontaires sains
Oui
Sexes éligibles pour l'étude
Tout
Méthode d'échantillonnage
Échantillon de probabilité
Population étudiée
Subjects will be recruited from the investigation centre's panel.
The participants will be selected on the basis of inclusion and non-inclusion criteria specific to the study and on their ability to comply with the constraints required by the protocol.
The participants will be definitely included in the study after a specific interview and a clinical examination
La description
Inclusion Criteria:
Related to the population:
- Females and/or males (with at least 25% of male)
- Age: adults from 18 to 40 years old and adolescent from 12 to 17 years old (33% to 50% of the total population)
- Considered "healthy subject" by the Investigator
- Being of Phototype I to IV
- Subject with combination to oily skin
- Subject who foresees sun exposure during the first 2 months of the study
- Subjects must be registered with health social security or health social insurance (if required by national regulations)
- Subject and/or parent(s)/legal representative(s) who have signed his/her/their written informed consent for his/her participation in the study (or his/her/their child participation in the study) and a photograph authorization
- For woman of childbearing potential: committing herself to use effective contraceptive method since at least 3 months before the beginning of the study and committing to it throughout the study
- Regular users of very high protection sunscreen products.
Related to the disease:
- For adults and adolescents: subject with mild to moderate acne with a total of 10 to 40 acne lesions (at least 5 non-inflammatory lesions (open and closed comedones) and at least 3 to 10 inflammatory lesions (papules and pustules) maximum on the face, excluding the nose area), at the inclusion.
- Subject prone to have recurrence of acne lesions in autumn (declarative)
Exclusion Criteria:
Related to the population:
- Having participated in another clinical trial within 4 weeks before the inclusion visit and for a longer period if required in the Investigator's opinion Taking part or planning to participate in another clinical trial during the study in the same or another investigation centre
- Breastfeeding or pregnant or not willing to take necessary precautions to avoid pregnancy during the study and for at least 3 months before the inclusion visit (for the woman of childbearing potential)
- Subject or parent(s)/legal representative(s) deprived of freedom by administrative or legal decision or under guardianship
- Subject or parent(s)/legal representative(s) not able to be contacted in case of emergency
- Subject admitted in a sanitary or social facility
- Subject planning a hospitalization during the study
Related to the disease
- Cutaneous pathology (psoriasis, atopic dermatitis, skin infectious disease of viral, bacterial, fungus or parasitic origin …) or dermatological condition (especially pityriasis versicolor, severe pigmentation disorders) on the studied zone other than acne liable to interfere with the data of the study
- Severe acne
- Clinical signs of hormonal disfunctions or hyperandrogenism
- Excessive exposure to sunlight or UV-rays within the previous month
- Having history of abnormal reactions from exposure to sunlight
- Use of self tanning product during the previous month History of hypersensitivity or intolerance to any cosmetic product
Related to treatments
- Use of a systemic or topical medication with anti-inflammatory or photosensitising products during the previous 2 weeks and for systemic medication with corticoids and/or antihistaminics during the previous 4 weeks
- Use of a systemic treatment for acne during the previous month for antibiotics, zinc gluconate and hormonal treatment and during the 6 previous months for isotretinoin
- Use of a topical treatment for acne during the previous month (benzoil peroxide, retinoid, antibiotics, azelaic acid…)
- Use of anti-acneic or anti-seborrheic cosmestic care (containing alpha hydroxy-acids, retinoic derivatives..) during the 15 previous days
- Use of other topical or systemic treatment during the previous weeks liable to interfere with the assessment of the cutaneous tolerance and efficacy of the studied product (according to the investigator's appreciation)
- Any surgery, chemical or physical treatment on the experimental area within the 12 months prior to the study or foreseeing it for the duration of the study
- Woman whose oral contraception is instaured or changed for less than 3 months
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
RV4857A arm
Application of the product before and during each sun exposure, at least twice a day. During sun exposures, the applications were renewed as often as necessary, in particular after swimming, perspiring, towelling, in order to ensure a good protection. On days of bad weather, the product was applied in the morning and at the beginning of the afternoon. |
RV4857A formula CD2110 is a sunscreen product
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Assessment of the dermatological physical signs
Délai: Change from Baseline to 30 minutes after product application, to 29 and 57 days later
|
The assessment of the dermatological physical signs is based on a visual examination
|
Change from Baseline to 30 minutes after product application, to 29 and 57 days later
|
|
Assessment of the dermatological functional signs
Délai: Change from Baseline to 30 minutes after product application, to 29 and 57 days later
|
The functional signs is assessed by questioning the subject
|
Change from Baseline to 30 minutes after product application, to 29 and 57 days later
|
|
Assessment of the ophthalmological physical signs
Délai: Change from Baseline to 30 minutes after product application, to 29 and 57 days later
|
The assessment of the ophthalmological physical signs is based on a dermatologist visual examination
|
Change from Baseline to 30 minutes after product application, to 29 and 57 days later
|
|
Assessment of the ophthalmological functional signs
Délai: Change from Baseline to 30 minutes after product application, to 29 and 57 days later
|
The functional signs is assessed by questioning the subject
|
Change from Baseline to 30 minutes after product application, to 29 and 57 days later
|
|
Assessment of the Tear film Break Up Time (BUT)
Délai: Change from Baseline to 30 minutes after product application, to 29 and 57 days later
|
The tear film break-up time is a test to measure the relative stability of the pre-corneal tear film.
This examination is performed by the same Ophthalmologist thanks to a biomicroscope after blinking (using a chronometer).
The measured time will be expressed in seconds
|
Change from Baseline to 30 minutes after product application, to 29 and 57 days later
|
|
Assessment of global tolerance assessment (dermatogical assesment), a 5-point scale
Délai: Change from Baseline to 29 and 57 days later
|
|
Change from Baseline to 29 and 57 days later
|
|
Assessment of global tolerance assessment (ophthalmological assessment), a 5-point scale
Délai: Change from Baseline to 29 days later
|
|
Change from Baseline to 29 days later
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change of the number of total acne lesions on the face
Délai: Change from Baseline to 29, 57 and 85 days later
|
by counting according to the method of Lucky
|
Change from Baseline to 29, 57 and 85 days later
|
|
Change of the number of non-inflammatory lesions (open and closed comedones) on the face
Délai: Change from Baseline to 29, 57 and 85 days later
|
by counting according to the method of Lucky
|
Change from Baseline to 29, 57 and 85 days later
|
|
Change of the number of inflammatory lesions (papules, pustules, nodules) on the face
Délai: Change from Baseline to 29, 57 and 85 days later
|
by counting according to the method of Lucky
|
Change from Baseline to 29, 57 and 85 days later
|
|
Assessment of the non-comedogenic potential
Délai: Change from Baseline to 29 days later
|
by statistical comparison of open and closed comedones counted by the investigator on the face before and after 28 days of application of investigational product
|
Change from Baseline to 29 days later
|
|
Change of the acne severity, assess by Global Acne Evaluation (GEA) on a 6-point scale
Délai: Change from Baseline to 29, 57 and 85 days later
|
|
Change from Baseline to 29, 57 and 85 days later
|
|
Evaluation of the global acne evolution on a 6-point scale
Délai: Change from Baseline to 29 and 57 days later
|
-1: Worsening, 0: No change,
|
Change from Baseline to 29 and 57 days later
|
|
Evaluation of the global product efficacy by the subjects themselves regarding rebound effect in Autumn
Délai: Change from Baseline to 85 days later
|
Questions Q24 and Q25 at D85 in the self-questionnaire
|
Change from Baseline to 85 days later
|
|
Assessment of the cosmetic acceptability and perceived efficacy of the product
Délai: Change from Baseline to 29 and 57 days later
|
The self subject assemsment consists of different questions concerning participants' perception of the product's efficacy (majority of scales ranging from 0 to 10 where 0 was the worst satisfaction and 10 the best one)
|
Change from Baseline to 29 and 57 days later
|
|
To evaluate the impact on Quality of Life of subjects through questionnaires
Délai: Change from Baseline to 29 and 57 days later
|
Quality of Life questionnaires consist of 10 questions concerning patients' perception of the impact of skin diseases on different aspects of their health-related quality of life over the last week
|
Change from Baseline to 29 and 57 days later
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Les enquêteurs
- Chaise d'étude: Pedro Contreiras Pinto, PhD, PhD Trials®
- Chercheur principal: Leonor Girão, MD, PhD Trials®
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude (Réel)
16 juillet 2020
Achèvement primaire (Réel)
9 novembre 2020
Achèvement de l'étude (Réel)
9 novembre 2020
Dates d'inscription aux études
Première soumission
29 septembre 2021
Première soumission répondant aux critères de contrôle qualité
7 décembre 2021
Première publication (Réel)
23 décembre 2021
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
23 décembre 2021
Dernière mise à jour soumise répondant aux critères de contrôle qualité
7 décembre 2021
Dernière vérification
1 décembre 2021
Plus d'information
Termes liés à cette étude
Autres numéros d'identification d'étude
- RV4857A202092
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
NON
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Non
Étudie un produit d'appareil réglementé par la FDA américaine
Non
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Acné
-
Elorac, Inc.Complété